Key advisers to the U.S. Food and Drug Administration (FDA) advised against approval for MDMA therapy for PTSD patients last week, questioning the drug’s sponsor, Lykos Therapeutics, on their results.

The CEO of Lykos Therapeutics Amy Emerson shares her frustration with the disapproval and details what went wrong with the evaluation of the FDA advisory committee.

Follow Kennedy on Twitter: @KennedyNation

Kennedy Now Available on YouTube: https://bit.ly/4311mhD.

Learn more about your ad choices. Visit podcastchoices.com/adchoices